Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group
PCD Bank, KE Caudle, JJ Swen… - Clinical …, 2018 - Wiley Online Library
Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group provide therapeutic recommendations for wellknown …
Pharmacogenetics Working Group provide therapeutic recommendations for wellknown …
Pharmacogenetics to guide cardiovascular drug therapy
JD Duarte, LH Cavallari - Nature Reviews Cardiology, 2021 - nature.com
Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …
selected cardiovascular therapies. The most common implementation in practice is …
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogeneticsguided warfarin dosing: 2017 update
JA Johnson, KE Caudle, L Gong… - Clinical …, 2017 - Wiley Online Library
This document is an update to the 2011 Clinical Pharmacogenetics Implementation
Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing …
Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing …
[HTML][HTML] Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
[HTML][HTML] Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study
Summary Background VKORC1 and CYP2C9 are important contributors to warfarin dose
variability, but explain less variability for individuals of African descent than for those of …
variability, but explain less variability for individuals of African descent than for those of …
[HTML][HTML] Recommendations for clinical CYP2C9 genotyping allele selection: a joint recommendation of the Association for Molecular Pathology and College of …
The goals of the Association for Molecular Pathology Pharmacogenomics (PGx) Working
Group of the Association for Molecular Pathology Clinical Practice Committee are to define …
Group of the Association for Molecular Pathology Clinical Practice Committee are to define …
Pharmacogenetics and cardiovascular disease—implications for personalized medicine
JA Johnson, LH Cavallari - Pharmacological reviews, 2013 - ASPET
The past decade has seen tremendous advances in our understanding of the genetic factors
influencing response to a variety of drugs, including those targeted at treatment of …
influencing response to a variety of drugs, including those targeted at treatment of …
Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs
T Hirota, S Eguchi, I Ieiri - Drug metabolism and pharmacokinetics, 2013 - jstage.jst.go.jp
Human cytochrome P450 (CYP) is a superfamily of hemoproteins which oxidize a number of
endogenous compounds and xenobiotics. The human CYP2C subfamily consists of four …
endogenous compounds and xenobiotics. The human CYP2C subfamily consists of four …
Genetic factors influencing warfarin dose in BlackAfrican patients: a systematic review and metaanalysis
IG Asiimwe, EJ Zhang, R Osanlou… - Clinical …, 2020 - Wiley Online Library
Warfarin is the most commonly used oral anticoagulant in subSaharan Africa. Dosing is
challenging due to a narrow therapeutic index and high interindividual variability in dose …
challenging due to a narrow therapeutic index and high interindividual variability in dose …
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism
Highlights•The interindividual variability of CYP2C members and its impact in drug
metabolism are reviewed.•Current advances in molecular modeling of CYP2C …
metabolism are reviewed.•Current advances in molecular modeling of CYP2C …